Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Factors Associated With 30-Day Mortality Rate in Respiratory Infections Caused by Streptococcus pneumoniae.

Cheng MP, Bogoch II, Green K, Plevneshi A, Rudnick W, Shigayeva A, McGeer A, Lee TC; Toronto Invasive Bacterial Diseases Network .

Clin Infect Dis. 2018 Apr 3;66(8):1282-1285. doi: 10.1093/cid/cix999.

PMID:
29140429
2.

Association of serotype with respiratory presentations of pneumococcal infection, Ontario, Canada, 2003-2011.

Shigayeva A, Rudnick W, Green K, Tyrrell G, Demczuk WH, Gold WL, Gubbay J, Jamieson F, Plevneshi A, Pong-Porter S, Richardson S, McGeer A; Toronto Invasive Bacterial Diseases Network.

Vaccine. 2016 Feb 3;34(6):846-53. doi: 10.1016/j.vaccine.2015.11.021. Epub 2015 Nov 18.

PMID:
26602266
3.

Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs.

Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, Johnstone J, Kitai I, Krajden S, Lovinsky R, Muller M, Powis J, Rau N, Walmsley S, Tyrrell G, Bitnun A, McGeer A; Toronto Invasive Bacterial Diseases Network.

Clin Infect Dis. 2016 Jan 15;62(2):139-47. doi: 10.1093/cid/civ803. Epub 2015 Sep 9.

PMID:
26354970
4.

In vitro activity of new cephalosporins vs Streptococcus pneumoniae from the Canadian Bacterial Surveillance Network: 2008-2011.

Green K, McGeer A, Rudnick W, Pong-Porter S, Patel SN, Low DE; Canadian Bacterial Surveillance Network (CBSN).

Curr Microbiol. 2014 Nov;69(5):763-7. doi: 10.1007/s00284-014-0622-8. Epub 2014 Jul 15.

5.

Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.

Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, Devlin R, Downey J, Katz K, Kitai I, Krajden S, Ostrowska K, Richardson D, Richardson S, Sarabia A, Silverman M, Simor AE, Tyrrell G, McGeer A; Toronto Invasive Bacterial Diseases Network.

Vaccine. 2013 Dec 2;31(49):5863-71. doi: 10.1016/j.vaccine.2013.09.049. Epub 2013 Oct 5.

PMID:
24099873
6.

Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010.

Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Shane A, Zhanel GG, Tyrrell GJ, Gilmour MW; Toronto Invasive Bacterial Diseases Network; Canadian Public Health Laboratory Network.

Can J Microbiol. 2012 Aug;58(8):1008-17. doi: 10.1139/w2012-073. Epub 2012 Jul 24.

PMID:
22827750
7.

Evaluation of coseasonality of influenza and invasive pneumococcal disease: results from prospective surveillance.

Kuster SP, Tuite AR, Kwong JC, McGeer A; Toronto Invasive Bacterial Diseases Network Investigators, Fisman DN.

PLoS Med. 2011 Jun;8(6):e1001042. doi: 10.1371/journal.pmed.1001042. Epub 2011 Jun 7.

8.

Evaluation of CLSI agar dilution method and Trek Sensititre broth microdilution panel for determining antimicrobial susceptibility of Streptococcus pneumoniae.

Zhang SX, Rawte P, Brown S, Lo S, Siebert H, Pong-Porter S, Low DE, Jamieson FB.

J Clin Microbiol. 2011 Feb;49(2):704-6. doi: 10.1128/JCM.01622-10. Epub 2010 Dec 1.

9.

Population-based surveillance for invasive pneumococcal disease in homeless adults in Toronto.

Plevneshi A, Svoboda T, Armstrong I, Tyrrell GJ, Miranda A, Green K, Low D, McGeer A; Toronto Invasive Bacterial Diseases Network.

PLoS One. 2009 Sep 29;4(9):e7255. doi: 10.1371/journal.pone.0007255.

10.

In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008.

Patel SN, Pillai DR, Pong-Porter S, McGeer A, Green K, Low DE.

J Antimicrob Chemother. 2009 Sep;64(3):659-60. doi: 10.1093/jac/dkp231. Epub 2009 Jul 3. No abstract available.

PMID:
19578080
11.

Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance.

Kumar D, Humar A, Plevneshi A, Siegal D, Franke N, Green K, McGeer A; Toronto Invasive Bacterial Diseases Network.

Bone Marrow Transplant. 2008 Apr;41(8):743-7. doi: 10.1038/sj.bmt.1705964. Epub 2008 Jan 7.

PMID:
18176614
12.

Decreased prevalence of virulence factors among ciprofloxacin-resistant uropathogenic Escherichia coli isolates.

Drews SJ, Poutanen SM, Mazzulli T, McGeer AJ, Sarabia A, Pong-Porter S, Rzayev Y, Willey B, Green K, Low DE.

J Clin Microbiol. 2005 Aug;43(8):4218-20.

13.

Prevalence and characterization of invasive isolates of Streptococcus pyogenes with reduced susceptibility to fluoroquinolones.

Powis J, McGeer A, Duncan C, Goren R, de Azavedo JC, Bast DJ, Pong-Porter S, Mazzulli T, Green K, Willey B, Low DE.

Antimicrob Agents Chemother. 2005 May;49(5):2130-2.

14.

Emergence of macrolide resistance in throat culture isolates of group a streptococci in Ontario, Canada, in 2001.

Katz KC, McGeer AJ, Duncan CL, Ashi-Sulaiman A, Willey BM, Sarabia A, McCann J, Pong-Porter S, Rzayev Y, de Azavedo JS, Low DE.

Antimicrob Agents Chemother. 2003 Jul;47(7):2370-2.

15.

Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.

Low DE, Muller M, Duncan CL, Willey BM, de Azavedo JC, McGeer A, Kreiswirth BN, Pong-Porter S, Bast DJ.

Antimicrob Agents Chemother. 2002 Apr;46(4):1119-21.

16.

In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.

de Azavedo JC, Trpeski L, Pong-Porter S, Matsumura S, Low DE.

Antimicrob Agents Chemother. 1999 Sep;43(9):2299-301.

Supplemental Content

Loading ...
Support Center